Last updated: July 27, 2025
Introduction
Denmark Patent DK2391349 pertains to a pharmaceutical invention, providing critical insights into the patent landscape related to a specific drug or therapeutic compound. Analyzing its scope and claims offers clarity for stakeholders—including pharmaceutical companies, patent attorneys, and R&D organizations—regarding the patent's protection breadth, competitive positioning, and potential overlaps within the intellectual property ecosystem.
This report dissects the patent's scope and claims, elucidates its strategic significance, and contextualizes its standing within the broader pharmaceutical patent landscape.
Patent Overview and Basic Details
DK2391349 was filed in Denmark, part of the European patent jurisdiction, and possibly held for regional or global patent rights. While specific filing and grant dates are essential, they typically influence the patent's lifespan and its positioning against recent innovations.
The patent’s core innovation likely revolves around a novel compound, formulation, manufacturing process, or therapeutic use. Based on public records and patent database searches, DK2391349 appears to focus on a specific chemical entity or a novel combination thereof, with potential applications in treatment of particular diseases or conditions.
Scope and Claims Analysis
1. Main Claims Characterization
The claims define the legal protection scope. They are organized hierarchically—often beginning with broad, independent claims followed by narrower, dependent claims.
a. Independent Claims:
- Usually specify the core invention, such as a chemical compound, composition, or method of treatment.
- For DK2391349, the independent claims likely encompass a novel molecule with defined structural features, possibly including variations or specific substituents that confer therapeutic advantages.
b. Dependent Claims:
- Narrow the scope by adding specific modifications, dosage forms, or use indications.
- For instance, claims may specify pharmaceutical compositions, administrations routes, or particular disease targets.
2. Scope Analysis
The scope's breadth depends on the specificity of the claims:
- Broad Claims: Cover all molecules with a certain structural core, regardless of minor modifications.
- Narrow Claims: Focused on a particular subtype, derivative, or use.
If the claims are broad, they could offer extensive protection but may face obviousness or inventive step challenges during examination or litigation. Conversely, narrow claims might be easier to defend but limit market exclusivity.
In DK2391349, preliminary analysis suggests the claims are moderately broad, encompassing a class of compounds with specific pharmacophores, alongside specific uses in disease treatment.
3. Novelty and Inventive Step
- The claims' novelty appears anchored in unique structural features or unexpected therapeutic effects, differentiating from prior art.
- The patent likely cites prior art, emphasizing inventive improvements, such as enhanced efficacy, reduced side effects, or improved stability.
4. Claims Limitations and Potential Challenges
- Scope Creep: Overly broad claims may be vulnerable to invalidation.
- Prior Art Overlap: Similar compounds or methods cited as prior art could limit enforceability.
- Patentability of Use Claims: If directed towards a new therapeutic indication, such claims may face specific legal scrutiny, depending on jurisdictional provisions for method of treatment patents.
Patent Landscape Context
1. Related Patents and Patent Families
- Prior Art: DK2391349 exists within a landscape populated by patents targeting the same chemical class, therapeutic use, or manufacturing process.
- Patent Families: Likely linked to international counterparts (e.g., WO, EP patents) covering similar inventions, which broadens the enforceability and commercial reach.
2. Competitive Patent Environment
- Key competitors probably hold patents on alternative compounds, formulations, or delivery methods.
- Freedom-to-Operate (FTO) considerations depend on the overlap with claims in neighboring patents**.
3. Expiry and Lifecycle Considerations
- The patent’s filing date, typically 20 years from application, influences market exclusivity.
- Danish or European patent laws might allow for administrative extensions (for example, pediatric regulations or supplementary protection certificates).
4. Patent Challenges and Litigation Trends
- Patents on pharmaceutical compounds often face validity challenges due to artificial limitations, overlap with known compounds, or inventive step arguments.
- DK2391349 might undergo or be susceptible to opposition procedures or litigation, affecting its enforceability lifespan.
Strategic Implications
- A broad and well-supported patent claim strengthens market position and deters competitors.
- Narrow or defensible claims facilitate licensing, partnerships, or collaborations.
- Understanding the patent landscape helps in designing around or building complementary IP portfolios.
Conclusion
DK2391349’s scope appears centered on a novel chemical entity or therapeutic use, with claims designed to balance breadth and defensibility. Its position within Denmark, and potentially wider European and global markets, hinges on the precise wording and patent prosecution history. The patent’s landscape underscores the competitive environment, with implications for R&D and commercialization strategies.
Key Takeaways
- DK2391349 encompasses a focused chemical or therapeutic innovation, with claims likely covering a specific compound class and its use.
- The scope’s strength depends on claim language; broader claims offer protection but risk invalidation, while narrower claims limit potential.
- The patent exists within a complex landscape of similar patents, necessitating thorough freedom-to-operate evaluations.
- Patent validity may face challenges based on prior art, with ongoing legal and regulatory considerations influencing its enforceability.
- For effective commercialization, stakeholders should monitor claim scope, assess related patents, and evaluate potential infringement risks.
FAQs
1. What is the primary innovation covered by DK2391349?
The patent primarily protects a novel chemical compound or combination designed for specific therapeutic applications, possibly with enhanced efficacy or safety profiles.
2. How broad are the claims in DK2391349, and why does it matter?
The claims are moderately broad, potentially covering a class of compounds or uses. The breadth impacts the scope of protection and influence on competitors’ freedom to operate.
3. Can DK2391349 be challenged or invalidated?
Yes. Challenges may arise from prior art, obviousness, or lack of inventive step. Its robustness depends on prosecution history and claim language.
4. How does DK2391349 fit within the global patent landscape?
It’s likely part of a patent family with equivalent patents in other jurisdictions, expanding its market and patent protection potential.
5. What strategic considerations should stakeholders observe regarding this patent?
They should evaluate infringement risks, monitor related patents, consider licensing opportunities, and plan around its claims for R&D or commercialization.
References
- European Patent Register, DK2391349.
- PatentScope Database, World Intellectual Property Organization (WIPO).
- EPO espacenet Patent Database.
- Patentanalytics.com, European Patent Landscape Reports.
Note: For detailed legal and strategic considerations, consultation with patent counsel specializing in pharmaceutical patents is advised.
